Exact(1)
Given rapid development of these new biomarkers, can we make randomized trials more adaptable to a changing landscape?
Similar(59)
Our study is retrospective because the rarity of this neoplasia makes randomized trials infeasible.
The rarity of the disease, however, makes randomized trials virtually impossible in a single institution or nation.
"That is why we do randomized trials".
This makes randomized controlled trials very attractive, though no panacea, since the treatment and control groups may not be representative of the population in which policy-makers hope to apply the causal conclusions, and the causal consequences of the intervention might differ across different subgroups within the control and treatment groups (Worrall 2007).
The rarity of severe complications of this disease in children makes randomized clinical trials in immune thrombocytopenia (ITP) unfeasible.
Ideally, service effectiveness should be studied before a service is launched; however, in practice, new services are introduced due to market demands, making randomized controlled trials difficult to apply.
14 Fiscal interventions are delivered at the population level, making randomized controlled trials of their effect difficult; hence, mathematical models have been used to assess the potential effects of these interventions, including potential adverse consequences.
The rarity of severe complications of the disease in children makes randomized clinical prevention trials unfeasible [ 1].
Even though some attempts have been made to conduct randomized trials to assess interventions for reducing sick leave [ 19, 20], the execution of such experiments is challenging and not very commonly seen.
Although the low incidence of rare cancers makes large-scale randomized trials involving single histologies difficult to perform, drugs have been successfully developed in rare cancers using clinical trial designs that combine microscopic histologies.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com